Welcome to the e-CCO Library!

P587: Drug survival of vedolizumab-treated inflammatory bowel disease patients in a nationwide observational cohort study: ICC case series
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Biemans1,2*, C. van der Woude3, G. Dijkstra4, A. van der Meulen - de Jong5, B. Oldenburg6, N. de Boer7, C. Ponsioen8, A. de Vries3, J. Haans2, M. Pierik2, F. Hoentjen9, Dutch Initiative on Crohn and Colitis (ICC)

Created: Thursday, 21 February 2019, 9:14 AM
P587: Fermentation capacity of gut microbiota in patients with inflammatory bowel disease compared to healthy controls
Year: 2017
Source: ECCO '17 Barcelona
Authors:

McGowan M.1, Kokkorou M.2, Rebull M.1, Koh Y.3, Gaya D.R.4, Hansen R.5, Russell R.K.5, Gerasimidis K.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P587: Intestinal ultrasound (IUS) and magnetic resonance imaging (MRI) for monitoring of response to therapy in luminal Crohn's disease – a systematic review.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lovett, G.(1,2)*;Schulberg, J.D.(1,2);Hamilton, A.L.(1,2);Wilding, H.E.(3);Kamm, M.A.(1,2);Wright, E.K.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P587: Quality of care indicators in inflammatory bowel disease: local pilot study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Sarraj*1, F. Bravo1, M. Maude1, A. Macpherson1, P. Juillerat1

Created: Friday, 22 February 2019, 9:41 AM
P587: Utility of intestinal ultrasound in Inflammatory Bowel Disease patients on management decisions
Year: 2021
Source: ECCO'21 Virtual
Authors: Abraham, B.(1);Saleh, A.(2);Perry, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P588 vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Marino1, R. Domenis2, L. Biribin1, A. Cifù2, L. Navarria1, G. Scardino1, M. Fabris2

Created: Thursday, 30 January 2020, 10:12 AM
P588: Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jairath, V.(1,2,3)*;Zou, G.(2,3,4);Wang, Z.(3);Adsul, S.(5);Colombel, J.F.(6);D'Haens, G.R.(7);Freire, M.(5);Moran, G.W.(8,9);Peyrin-Biroulet, L.(10);Sandborn, W.J.(11);Sebastian, S.(12,13);Travis, S.(14);Vermeire , S.(15);Radulescu, G.(3);Sigler, J.(3);Mcfarlane, S.(3);Arya, N.(16);Beaton, M.(1);Bossuyt, P.(17);Green, D.(18);Harlan III, W.(19);Horynski, M.(20);Klopocka, M.(21,22);Petroniene, R.(23);Silverberg, M.S.(24);Wolanski, L.(25);Feagan , B.G.(1,2,3);
Created: Friday, 14 July 2023, 11:05 AM
P588: Steroid sparing effect of adalimumab in cortisone–depended ulcerative colitis patients
Year: 2021
Source: ECCO'21 Virtual
Authors: SinaDr., M.(1);Pengili, E.(1);Pemaj, X.(1);Osmanaj, D.(1);Bibolli, I.(1);Prifti, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P588: Switching from infliximab originator to a first biosimilar is safe and effective: A single-centre series with through levels and anti-drug antibodies determination
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Daperno*, C. Guiotto, A. Italia, A. Lavagna, A. Negri, E. Ercole, M. Cosimato, C. Rigazio, R. Rocca

Created: Thursday, 21 February 2019, 9:14 AM
P588: T cell response to SARS-CoV-2 mRNA vaccines by an interferon-gamma release immunoassay in patients with Inflammatory Bowel disease receiving anti-TNF and thiopurine treatment
Year: 2022
Source: ECCO'22
Authors: Mayorga Ayala, L.F.(1);Herrera-deGuise, C.(1);Esperalba, J.(2);Martinez-Gomez, X.(6);Céspedes Martinez, E.(1);Robles Alonso, V.(1);Jimenez, A.(1);Perez Martinez, Z.(1);Oller, E.(1);Ibarz, A.(1);Fernandez-Naval, C.(3);Martinez-Gallo, M.(4);Lopez Messeguer, M.(5);Casellas, F.(1);Borruel, N.(1);
Created: Friday, 11 February 2022, 3:56 PM
P588: Tacrolimus suppositories: a safe and effective treatment for treatment-refractory proctitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Smith*1, H. Weekes2, L. Morgan2, M. Parkes1, J. C. Lee1

Created: Friday, 22 February 2019, 9:41 AM
P588: Ustekinumab for the treatment of Crohn's disease patients with TNF antagonist induced psoriasis. Real life experience from a tertiary referral center through week 54
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kuehbacher T.*1, Abu Hashem R.1, Langel N.1, Schreiber S.2, Drvarov O.1

Created: Wednesday, 20 February 2019, 10:36 AM
P589 Longer-term outcomes in patients with Crohn’s disease who are primary non-responders to anti-TNF in a single UK centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. HODGES, J. Saunders, F. Betteridge

Created: Thursday, 30 January 2020, 10:12 AM
P589: A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. Kantasiripitak1, E. Dreesen*1, I. Detrez1, S. Stefanović2, D. Drobne2, S. Vermeire3,4, M. Ferrante3,4, A. Gils1

Created: Friday, 22 February 2019, 9:41 AM
P589: Adherence to medical treatment in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Jardak1*, L. Hamzaoui1,2,3, K. Agar2, M. Medhioub2, A. Khsiba2, M.M. Azouz2

Created: Thursday, 21 February 2019, 9:14 AM
P589: Effectiveness of partial enteral nutrition to treat adults with Crohn's Disease who lost response to biological therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nardone, O.M.(1)*;Calabrese, G.(2);Alfonsi, L.(3);Rispo, A.(2);La Mantia , A.(2);Fierro, G.(2);Ferrante, M.(2);Testa, A.(2);Guarino, A.D.(2);D'Alessandro, E.(2);Pasanisi, F.(3);Castiglione, F.(2);
Created: Friday, 14 July 2023, 11:05 AM
P589: Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Paramsothy S.*1,2, Paramsothy R.3, Kamm M.4, Kaakoush N.5, Mitchell H.6, Rubin D.2, Castaño-Rodríguez N.6

Created: Wednesday, 20 February 2019, 10:36 AM
P589: Stable Trends in Radiation Exposure Amongst Patients with a New Diagnosis of Inflammatory Bowel Disease at an Irish Tertiary Referral Hospital
Year: 2021
Source: ECCO'21 Virtual
Authors: Matthews, T.J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P589: Total thiopurine exposure and impact on the development of keratinocyte carcinomas in Inflammatory Bowel Disease patients; a case control study
Year: 2022
Source: ECCO'22
Authors: Jansen, F.M.(1);Lubeek, S.(2);den Broeder, N.(3);Savelkoul, E.(1);Marcus, C.(1);Hoentjen, F.(1,4);van Dop, W.(1);
Created: Friday, 11 February 2022, 3:56 PM
P590 Outcomes of patients treated with sequential anti-TNF therapy in a tertiary referral centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Rowan, J. O’Donnell, N. Cullen, A. O’Toole, K. Boland

Created: Thursday, 30 January 2020, 10:12 AM